EU Fragrance Allergen Labeling: The August 2026 Deadline That Changes What Goes on Your Cosmetics Label

Eleven days from now, something changes on every EU cosmetics label that contains fragrance.

As of 1 August 2026, newly manufactured cosmetic products placed on the European market must comply with the updated fragrance allergen declaration requirements under Regulation (EC) No 1223/2009. The list of substances requiring label disclosure has been significantly expanded beyond the 26 allergens that European manufacturers have been managing since 2003. If your current labels were compliant eighteen months ago, they may not be compliant next month.

We’ve been fielding a steady stream of calls from European cosmetics brands over the past 60 days about exactly this issue — and the pattern is consistent. Most manufacturers understand that something has changed. What they’re less clear on is which substances are now affected, which concentration thresholds trigger a declaration obligation, and whether their existing audit trail holds up if a market surveillance authority comes knocking.

This post covers the practical compliance picture: what the original framework required, what has changed, the concentration thresholds that actually matter in practice, and what a realistic compliance sprint looks like with time this short.

The Original 26 Allergens — And Why They Were Never the Whole Story

The requirement to declare fragrance allergens on cosmetics labels in Europe was first introduced in 2003 through Directive 2003/15/EC — the 7th Amendment to the Cosmetics Directive, subsequently incorporated into Annex III of Regulation (EC) No 1223/2009. That original requirement covered 26 fragrance substances.

The declaration thresholds were, and remain, straightforward: a fragrance allergen must appear individually in the ingredient list if it is present at ≥0.001% (10 ppm) in a leave-on product, or ≥0.01% (100 ppm) in a rinse-off product. Those thresholds were derived from contact allergy research available at the turn of the millennium.

The original 26 include substances most experienced formulators know well — linalool, limonene, citronellol, geraniol, eugenol, isoeugenol, benzyl salicylate, cinnamal, farnesol, and others. If you’ve been formulating or auditing EU-marketed cosmetics for more than a decade, these are names you’ve seen on every fragrance safety review.

The problem the EU’s Scientific Committee on Consumer Safety (SCCS) identified over subsequent years was that contact allergy to fragrance was being systematically underestimated by a list frozen in 2003. Epidemiological data showed that between 1% and 4% of the general population in Europe has a fragrance-related contact allergy — a significant consumer safety burden. SCCS Opinion SCCS/1631/21, adopted in 2021, identified a substantial number of additional fragrance substances with sufficient sensitization data to warrant labeling requirements, and that scientific work fed directly into the regulatory update that brings us to this August’s deadline.

What the Updated Annex III Requirements Actually Cover

The updated framework adds a material number of fragrance substances to the mandatory declaration list, extending the same core logic: declare the substance by its INCI name in the ingredient list when it is present above the applicable threshold concentration in the finished product.

The substances added span both synthetic fragrance materials and naturally derived components found in essential oil complexes and botanical extracts. That second category is where we see the most surprises in label audits. Many manufacturers believe that purchasing a “natural” fragrance or essential oil blend insulates them from expanded allergen obligations. It doesn’t. The regulatory obligation attaches to the substance in the finished product, not to how that substance was derived.

There is also a specific point about the “Parfum” declaration that causes persistent confusion. Under Article 19(1)(g) of Regulation (EC) No 1223/2009, the collective term “Parfum” or “Aroma” may be used in the ingredient list to indicate the presence of a fragrance mixture — because fragrance compositions are legitimately protected as trade secrets. But that collective term does not exempt you from separately disclosing any allergen within that mixture that is present above threshold. Both declarations must appear on the label: “Parfum” to indicate the mixture, and the individual INCI name of each allergen above threshold.

This dual-disclosure requirement is the most common gap we find in label reviews. A leave-on product formulated with a 1.5% floral fragrance blend might contain, say, 0.0015% farnesol, 0.0020% linalool oxide, and 0.0018% benzyl benzoate — each above the 10 ppm leave-on threshold. Each must appear in the ingredient list independently, alongside “Parfum.”

Three Concentration Realities That Catch Manufacturers Off Guard

The cascade calculation from blend to finished product. Allergen threshold compliance is assessed at finished product concentration, not at blend concentration. A substance present at 0.1% within a fragrance blend that is used at 1.5% in the finished formula contributes 0.0015% to that finished product — above the 0.001% leave-on threshold. Many manufacturers work from IFRA usage guidelines or supplier compositional notes without translating blend percentages back to finished product concentrations, and that translation step is precisely where declaration gaps emerge.

Natural materials carry the same obligation as synthetics. Lavender oil naturally contains linalool and linalool oxide. Bergamot contains limonene. Rose absolute contains geraniol, citronellol, eugenol, and benzyl benzoate — several of which appear on the restricted list. A supplier certificate describing an ingredient as “100% natural” or “COSMOS-certified” does not change the labeling obligation. If an allergen is present above threshold in the finished product, it must be declared regardless of origin.

Rinse-off products are not the low-risk category they appear to be. The 0.01% threshold for rinse-off products is ten times higher than for leave-ons, but the declaration obligation still applies. A shampoo using a citrus-forward fragrance blend at 2% could contain individual allergens above 100 ppm. Rinse-off product labels tend to receive less rigorous allergen audit scrutiny than leave-on products, which is why we see more gaps there in practice.

Five Steps to Complete Your Fragrance Allergen Audit Before the Deadline

With days rather than weeks remaining before the new-product deadline, the compliance process needs to move quickly but methodically.

Step 1: Obtain full quantitative fragrance compositions from every supplier. Not IFRA certificates. Not safety data sheets. You need a full quantitative composition listing every substance present above 0.001% in the blend, with CAS numbers, provided under a non-disclosure agreement if necessary. If a supplier refuses to provide this, that is a significant supply chain risk that needs to be escalated — it effectively makes allergen compliance impossible to verify independently.

Step 2: Translate blend concentrations to finished product concentrations. For each allergen-relevant substance in each blend, multiply the percentage in the blend by the percentage of the blend used in your finished formula. Apply the appropriate threshold: 0.001% for leave-on products, 0.01% for rinse-off products.

Step 3: Cross-reference against the full updated Annex III list. The original 26 substances plus all additions from the 2023 regulatory update. If you’re working from a reference list that hasn’t been updated since 2022 or earlier, it almost certainly needs refreshing. The ECHA and European Commission portals maintain the current Annex III text.

Step 4: Update ingredient declarations across affected SKUs. Any substance above threshold must appear in the ingredient list by its INCI name. Ingredients are listed in descending concentration above 1%, and then in any order below 1% — fragrance allergens typically fall in the sub-1% section where order is flexible, but their presence is not.

Step 5: Update your Product Information File. The PIF under Article 11 of Regulation 1223/2009 must include a description of the cosmetic product formula. If your allergen analysis changes the ingredient declaration, the PIF documentation must reflect that update — the label, the CPNP notification data, and the PIF need to be internally consistent.

After August 2026: What the 2028 Transitional Window Actually Means

The 1 August 2026 deadline applies to newly manufactured products. Products that were manufactured before that date and are already in distribution channels — in warehouses, at retailers, in transit — have a transitional window allowing them to remain on the market until 1 August 2028.

This is not a comfortable two-year buffer in practice. Many brands have 12-to-24-month distributor stock cycles, and the moment a new production batch is manufactured after August 1, it must comply. The transitional provision protects existing stock that was lawfully manufactured and labeled under the previous requirements — it does not extend any permission to continue manufacturing non-compliant products.

The practical implication: if you manufacture a new batch in September 2026 without updated allergen declarations, that batch is non-compliant from the moment it’s made, regardless of any stock in the warehouse that predates August 1.

What Market Surveillance Will Focus On

France’s DGCCRF, Germany’s BVL, Italy’s ISS — the national competent authorities responsible for cosmetics market surveillance under Article 22 of Regulation 1223/2009 — conduct targeted label compliance inspections, and the expanded fragrance allergen requirements are highly likely to become an active enforcement focus over the next 12 to 18 months. The regulatory change is recent, the deadline is specific, and label checks are among the lowest-friction enforcement actions available to authorities.

A non-compliant label creates a direct, legible paper trail. Your CPNP notification, your PIF, and your physical label all need to be consistent with each other. An authority finding “Parfum” in a leave-on cream without accompanying allergen INCI listings — when those allergens are demonstrably present in the formulation — will treat that as a labeling violation under Article 19, not an administrative oversight with an easy correction path.

If August 1 Is Too Close

If your corrected labels won’t be production-ready by August 1, the cleanest options are straightforward: pause new manufacturing runs on affected SKUs until labels are updated, and don’t create a new wave of non-compliant stock. Quarantine any finished goods manufactured after the deadline under non-compliant labels before they reach trade. And engage your Responsible Person to document the transition clearly.

The worst outcome isn’t the August 1 deadline itself — it’s continuing to manufacture under non-compliant labels through September and October because the label correction felt like a project for next quarter.

We work with cosmetics manufacturers across France, Germany, the Benelux countries, and Southern Europe who are navigating exactly this transition right now. The analytical work — allergen composition analysis and finished-product threshold calculations — and the label update process are not complicated. But they are time-sensitive, and the window to move cleanly is measured in days.

---

Written by Nour Abochama, Quality & Regulatory Advisor, Care Europe | VP Operations, Qalitex. Learn more about our team

Talk to our team about EU market entry. Contact us

Related from our network

• Cosmetic Ingredient Testing and ISO 17025 Accreditation — Qalitex Laboratories provides ISO 17025-accredited testing for cosmetic raw materials and finished products, including fragrance allergen quantification for EU compliance documentation.
• Cosmetics Compliance for the Canadian Market — Androxa supports European cosmetics brands seeking Health Canada compliance, including ingredient safety assessments aligned with Canadian regulatory requirements.